FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019927301> ?p ?o ?g. }

• W2019927301 endingPage "2249" @default.
• W2019927301 startingPage "2241" @default.
• W2019927301 abstract "Δ9,11 modifications of glucocorticoids (21-aminosteroids) have been developed as drugs for protection against cell damage (lipid peroxidation; lazaroids) and inhibition of neovascularization (anecortave). Part of the rationale for developing these compounds has been the loss of glucocorticoid receptor binding due to the Δ9,11 modification, thus avoiding many immunosuppressive activities and deleterious side effect profiles associated with binding to glucocorticoid and mineralocorticoid receptors. We recently demonstrated that anecortave acetate and its 21-hydroxy analog (VBP1) do, in fact, show glucocorticoid and mineralocorticoid receptor binding activities, with potent translocation of the glucocorticoid receptor to the cell nucleus. We concluded that Δ9,11 steroids showed novel anti-inflammatory properties, retaining NF-κB inhibition, but losing deleterious glucocorticoid side effect profiles. Evidence for this was developed in pre-clinical trials of chronic muscle inflammation. Here, we describe a drug development program aimed at optimizing the Δ9,11 chemistry. Twenty Δ9,11 derivatives were tested in in vitro screens for NF-κB inhibition and GR translocation to the nucleus, and low cell toxicity. VBP15 was selected as the lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability. Phamacokinetics were similar to traditional glucocorticoid drugs with terminal half-life of 0.35 h (mice), 0.58 h (rats), 5.42 h (dogs), and bioavailability of 74.5% (mice), and 53.2% (dogs). Metabolic stability showed ≥80% remaining at 1 h of VBP6 and VBP15 in human, dog, and monkey liver microsomes. Solubility, permeability and plasma protein binding were within acceptable limits. VBP15 moderately induced CYP3A4 across the three human hepatocyte donors (24-42%), similar to other steroids. VBP15 is currently under development for treatment of Duchenne muscular dystrophy." @default.
• W2019927301 created "2016-06-24" @default.
• W2019927301 creator A5024664136 @default.
• W2019927301 creator A5031586466 @default.
• W2019927301 creator A5040081755 @default.
• W2019927301 creator A5070954626 @default.
• W2019927301 creator A5091023992 @default.
• W2019927301 date "2013-04-01" @default.
• W2019927301 modified "2023-09-24" @default.
• W2019927301 title "VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid" @default.
• W2019927301 cites W1510328004 @default.
• W2019927301 cites W1515149692 @default.
• W2019927301 cites W1997646447 @default.
• W2019927301 cites W2003222772 @default.
• W2019927301 cites W2013623387 @default.
• W2019927301 cites W2031679716 @default.
• W2019927301 cites W2033797333 @default.
• W2019927301 cites W2034374778 @default.
• W2019927301 cites W2049691169 @default.
• W2019927301 cites W2060127676 @default.
• W2019927301 cites W2063093518 @default.
• W2019927301 cites W2065094515 @default.
• W2019927301 cites W2102610804 @default.
• W2019927301 cites W2118502815 @default.
• W2019927301 cites W2125781987 @default.
• W2019927301 cites W2130353405 @default.
• W2019927301 cites W2130593829 @default.
• W2019927301 cites W2142852486 @default.
• W2019927301 cites W2147652719 @default.
• W2019927301 cites W2152206883 @default.
• W2019927301 cites W2154110852 @default.
• W2019927301 cites W2164415668 @default.
• W2019927301 cites W2170677280 @default.
• W2019927301 cites W4295334631 @default.
• W2019927301 doi "https://doi.org/10.1016/j.bmc.2013.02.009" @default.
• W2019927301 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4088988" @default.
• W2019927301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23498916" @default.
• W2019927301 hasPublicationYear "2013" @default.
• W2019927301 type Work @default.
• W2019927301 sameAs 2019927301 @default.
• W2019927301 citedByCount "46" @default.
• W2019927301 countsByYear W20199273012013 @default.
• W2019927301 countsByYear W20199273012014 @default.
• W2019927301 countsByYear W20199273012015 @default.
• W2019927301 countsByYear W20199273012016 @default.
• W2019927301 countsByYear W20199273012017 @default.
• W2019927301 countsByYear W20199273012018 @default.
• W2019927301 countsByYear W20199273012019 @default.
• W2019927301 countsByYear W20199273012020 @default.
• W2019927301 countsByYear W20199273012021 @default.
• W2019927301 countsByYear W20199273012022 @default.
• W2019927301 countsByYear W20199273012023 @default.
• W2019927301 crossrefType "journal-article" @default.
• W2019927301 hasAuthorship W2019927301A5024664136 @default.
• W2019927301 hasAuthorship W2019927301A5031586466 @default.
• W2019927301 hasAuthorship W2019927301A5040081755 @default.
• W2019927301 hasAuthorship W2019927301A5070954626 @default.
• W2019927301 hasAuthorship W2019927301A5091023992 @default.
• W2019927301 hasBestOaLocation W20199273012 @default.
• W2019927301 hasConcept C104317684 @default.
• W2019927301 hasConcept C126322002 @default.
• W2019927301 hasConcept C1292079 @default.
• W2019927301 hasConcept C134018914 @default.
• W2019927301 hasConcept C150194340 @default.
• W2019927301 hasConcept C170493617 @default.
• W2019927301 hasConcept C181389837 @default.
• W2019927301 hasConcept C185592680 @default.
• W2019927301 hasConcept C189135053 @default.
• W2019927301 hasConcept C2776069600 @default.
• W2019927301 hasConcept C2780841215 @default.
• W2019927301 hasConcept C55493867 @default.
• W2019927301 hasConcept C59300778 @default.
• W2019927301 hasConcept C59493245 @default.
• W2019927301 hasConcept C71924100 @default.
• W2019927301 hasConcept C86803240 @default.
• W2019927301 hasConcept C98274493 @default.
• W2019927301 hasConceptScore W2019927301C104317684 @default.
• W2019927301 hasConceptScore W2019927301C126322002 @default.
• W2019927301 hasConceptScore W2019927301C1292079 @default.
• W2019927301 hasConceptScore W2019927301C134018914 @default.
• W2019927301 hasConceptScore W2019927301C150194340 @default.
• W2019927301 hasConceptScore W2019927301C170493617 @default.
• W2019927301 hasConceptScore W2019927301C181389837 @default.
• W2019927301 hasConceptScore W2019927301C185592680 @default.
• W2019927301 hasConceptScore W2019927301C189135053 @default.
• W2019927301 hasConceptScore W2019927301C2776069600 @default.
• W2019927301 hasConceptScore W2019927301C2780841215 @default.
• W2019927301 hasConceptScore W2019927301C55493867 @default.
• W2019927301 hasConceptScore W2019927301C59300778 @default.
• W2019927301 hasConceptScore W2019927301C59493245 @default.
• W2019927301 hasConceptScore W2019927301C71924100 @default.
• W2019927301 hasConceptScore W2019927301C86803240 @default.
• W2019927301 hasConceptScore W2019927301C98274493 @default.
• W2019927301 hasIssue "8" @default.
• W2019927301 hasLocation W20199273011 @default.
• W2019927301 hasLocation W20199273012 @default.
• W2019927301 hasLocation W20199273013 @default.
• W2019927301 hasOpenAccess W2019927301 @default.

• next